{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-017859","form_type":"8-K","ticker":"ALEC","cik":"0001653087","company_name":"Alector, Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.856448+00:00","generated_at":"2026-06-15T22:16:16.371220+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Alector Q1 net loss $45.9M, cash $669.3M; on track for latozinemab INFRONT-3 regulatory engagement in mid-2023","bullets":["Revenue $16.5M (down $8M YoY); net loss $45.9M ($0.55/share) vs $44.6M ($0.54/share) in Q1 2022.","Cash, equivalents and investments $669.3M; management expects runway through 2025.","On track to discuss INFRONT-3 (latozinemab in FTD-GRN) with regulators mid-2023; data readout early 2025.","Received $17.8M milestone from AbbVie for AL002 LTE enrollment; INVOKE-2 top-line data expected Q4 2024.","2023 guidance: collaboration revenue $15-25M, R&D expense $225-245M, G&A $60-70M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-017859","json":"https://secwatch.observer/filing/0000950170-23-017859.json","markdown":"https://secwatch.observer/filing/0000950170-23-017859.md","text":"https://secwatch.observer/filing/0000950170-23-017859.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1653087/000095017023017859/0000950170-23-017859-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1653087/000095017023017859/alec-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T22:16:16.371220+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3538d899f1fdb87d2bca46dae6931c1da9bd0c8d","claim":"Alector, Inc. reported financial results for the quarter ended March 31, 2023.","evidence_excerpt":"On May 4, 2023, Alector, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1653087/000095017023017859/0000950170-23-017859-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}